Mar 14, 2023 4:31pm EDT Sonnet BioTherapeutics to Present Clinical Data from the SB101 Study with SON-1010 at the AACR 2023 Annual Meeting
Feb 13, 2023 8:00am EST Sonnet BioTherapeutics Provides Fiscal Year 2023 First Quarter Business and Earnings Update
Feb 08, 2023 8:00am EST Sonnet BioTherapeutics Announces Pricing of $15.0 Million Underwritten Public Offering
Feb 01, 2023 8:00am EST Sonnet BioTherapeutics Announces Successful Completion of Two IND-Enabling Toxicology Studies with SON-1210 in Non-Human Primates
Jan 19, 2023 8:00am EST Sonnet BioTherapeutics Announces Pharmacokinetic and Pharmacodynamic Data in a Phase 1 Dose-Escalation Trial of SON-1010
Jan 09, 2023 8:00am EST Sonnet BioTherapeutics Announces a Collaboration with Roche for the Clinical Evaluation of SON-1010 with atezolizumab in Ovarian Cancer
Dec 15, 2022 4:05pm EST Sonnet BioTherapeutics Provides Fiscal Year 2022 Business and Financial Update
Nov 02, 2022 8:00am EDT Sonnet BioTherapeutics Announces Interim Data in Two Phase 1 Dose-Escalation Trials of SON-1010
Nov 01, 2022 4:05pm EDT Sonnet BioTherapeutics Announces Webcast to Discuss Interim Data from the Company’s Phase 1 Dose-Escalation Trials of SON-1010 on November 2, 2022
Oct 31, 2022 7:30am EDT Sonnet BioTherapeutics Announces an Agreement with Janssen for the Evaluation of Three Sonnet Product Candidates
